Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C

Trial Profile

Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Apr 2013 Planned end date changed from 1 Apr 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 15 Aug 2012 Actual patient number changed from 7725 to 7727 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top